KRAS-mutant allele-specific inhibitors, such as AMG 510 (sotorasib) and MRTX849 (adagrasib), can target G12C-mutant KRAS and suppress downstream signaling, thus killing tumor cells harboring KRASG12C mutations [12, 13]. This evidence concerns the gene KRAS and neoplasm.